HIV preexposure prophylaxis: new data and potential use.

@article{Celum2011HIVPP,
  title={HIV preexposure prophylaxis: new data and potential use.},
  author={Connie L Celum},
  journal={Topics in antiviral medicine},
  year={2011},
  volume={19 5},
  pages={181-5}
}
HIV preexposure prophylaxis (PrEP) has demonstrated efficacy in 4 studies: 1) the CAPRISA 004 trial of pericoital administration of 1% tenofovir gel showed moderate (39%) efficacy in reducing risk of HIV acquisition in young women; 2) the iPrEx trial of daily oral emtricitabine/tenofovir had moderate (44%) efficacy in reducing risk of HIV acquisition among high-risk men who have sex with men (MSM); 3) the Partners PrEP Study in African HIV-serodiscordant couples, in which the HIV-seronegative… CONTINUE READING